p-value / HR (95% CI) / p-value / HR (95% CI)
Diagnosis time / 1980-1987 / 1 / 1
1988-1998 / 0.88 / 0.98 (0.8-1.2) / 0.07 / 1.19 (1.0-1.4)
/ 1999-2008 / 0.001 / 0.57 (0.4-0.8) / 0.77 / 0.96 (0.7-1.2)
Age / 20-41 / 1 / 1
41-51 / 0.01 / 0.77 (0.6-0.9) / 0.51 / 0.94 (0.7-1.1)
51-65 / 0.001 / 0.71 (0.6-0.9) / 0.06 / 1.21 (1.0-1.5)
65-90 / 0.0005 / 0.63 (0.5-0.8) / <0.0001 / 2.71 (2.2-3.2)
Localisation / Medial / 1 / 1
Lateral / <0.0001 / 0.75 (0.7-0.9) / 0.02 / 0.88 (0.8-0.98)
T-stage / 1 / 1 / 1
2 / <0.0001 / 1.74 (1.5-2.0) / <0.0001 / 1.54 (1.4-1.7)
N-stage / Negative / 1 / 1
Micro / 0.9 / 0.97 (0.6-1.5) / 0.92 / 0.98 (0.7-1.4)
Positive / <0.0001 / 2.10 (1.8-2.5) / <0.0001 / 1.72 (1.5-2.0)
ER-status / Negative / 1 / 1
Positive / 0.33 / 1.13 (0.9-1.4) / 0.36 / 0.91 (0.8-1.1)
PR-status / Negative / 1 / 1
Positive / 0.01 / 0.73 (0.8-0.9) / 0.34 / 0.91 (0.7-1.1)
HER2-status / Negative
Positive / 0.13 / 1
0.68 (0.4-1.1) / 0.6 / 1
0.89 (0.6-1.3)
Differentiation grade / 1 / 1 / 1
2 / <0.0001 / 2.53 (1.9-3.3) / 0.0001 / 1.39 (1.2-1.6)
Margin invasive ca
Margin DCIS / 3
Free
Irradical/Not Free
Free
Irradical/Not free
no DCIS / <0.0001
0.92
0.42
0.88 / 3.98 (3.0-5.3)
1
1.01 (0.8-1.3)
1
1.16 (0.8-1.7)
0.98 (0.7-1.3) / <0.0001
1
0.23
0.91
/ 2.10 (1.8-2.5)
1
1.00 (0.8-1.2)
1
1.18 (0.9-1.6)
0.91 (0.8-1.3)
Chemotherapy / No
Yes / 0.01 / 1
0.76 (0.6-0.9) / 0.05 / 1
0.84 (0.7-1)
Hormonal therapy / No
Yes / 0.21 / 1
0.89 (0.7-1.1) / 0.12 / 1
0.89 (0.8-1.1)
RT boost / No / 1 / 1
Yes / 0.89 / 0.98 (0.8-1.2) / 0.22 / 1.12 (0.9-1.3)
Table 3: Result of multivariable analysis for risk factors for distant metastases and overall survival